Madison startup advances three-in-one cancer drug rooted at UW
Co-D Therapeutics, a University of Wisconsin–Madison spinoff, is developing a three-drug cocktail to battle a wide range of cancers. The first target for Co-D is angiosarcoma, a rare and lethal cancer that arises from blood vessels.
The company’s submicroscopic package contains paclitaxel, a standard cancer drug, combined with two other drugs designed to reduce the resistance that often develops against chemotherapy drugs.
The triple-threat product was invented by two of Co-D’s co-founders, chief scientific officer Glen Kwon, a professor of pharmaceutical science at UW–Madison, and chief medical officer Kevin Kozak, a radiation oncologist now at Mercy Health System in Janesville.